Bafna Pharmaceuticals Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter

The Bafna Pharmaceuticals Q2 results FY27 announcement is the next scheduled earnings event for Bafna Pharmaceuticals Ltd., a contract and own-brand manufacturer of finished pharmaceutical formulations, mainly oral solids and liquids, selling domestically and into registered export markets. The stock traded at Rs 301.60 on the NSE on 9 September 2026, down 2.00% from the previous close of Rs 307.75, about 5.3% below its 52-week high of Rs 318.50 and 218.2% above its 52-week low of Rs 94.77.

What makes the Bafna Pharmaceuticals Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 35.47 crore of revenue and a profit of Rs 3.12 crore, while the most recent quarter on record, Q1 FY27, produced Rs 26.58 crore and a profit of Rs 0.08 crore. Everything below is built from those reported figures rather than from any forecast.

Click Here – Get Free Investment Predictions

When Is the Bafna Pharmaceuticals Q2 Results FY27 Date?

The Bafna Pharmaceuticals Q2 results date for FY27 is not confirmed. As of 9 September 2026, Bafna Pharmaceuticals Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.

What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Bafna Pharmaceuticals Q2 results date becomes public through that filing rather than through any advance announcement.

The Bafna Pharmaceuticals Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Bafna Pharmaceuticals.

Bafna Pharmaceuticals Q2 Results Expectations: What the Market Is Actually Tracking

No verified analyst estimate for the Bafna Pharmaceuticals Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Bafna Pharmaceuticals. The Bafna Pharmaceuticals Q2 results watchlist below is built from what the company has actually reported and disclosed.

The first is the collapse in Q1 FY27. Revenue fell to Rs 26.58 crore from Rs 42.24 crore, the operating margin to 3.35% from 8.40%, and operating profit to Rs 0.89 crore. That is the weakest quarter in the visible record.

The second is that the margin has fallen steadily rather than in one step. It ran 14.64%, 12.07%, 7.97%, 8.40% and 3.35% across the five quarters, so the September 2025 base of 12.07% is a long way above the current level.

The third is that reported profit is untaxed. The effective rate was zero in four of the five quarters and negative in the fifth, reflecting carried-forward losses from the company's earlier insolvency, so profit is not comparable to a normal taxpayer.

Check Bafna Pharmaceuticals Ltd. Live Fundamentals on the Univest Screener

Bafna Pharmaceuticals Q2 Results Preview: The Q1 FY27 Actuals It Builds On

Bafna Pharmaceuticals Ltd. reported revenue of Rs 26.58 crore in Q1 FY27, down 23.22% from Rs 34.62 crore in Q1 FY26, and a profit of Rs 0.08 crore at the net level, down 97.64% from Rs 3.39 crore in Q1 FY26. These are reported actuals, not estimates.

Sequentially, revenue was down 37.07% over the March 2026 quarter figure of Rs 42.24 crore, and net profit was down 97.09% from Rs 2.75 crore in Q4 FY26. Operating margin stood at 3.35% in Q1 FY27 against 12.07% in the September 2025 quarter, which is the comparison the Bafna Pharmaceuticals Q2 results print will be read against.

Q2 FY26 Base: The Comparison Bafna Pharmaceuticals Q2 Results FY27 Must Beat

Bafna Pharmaceuticals Ltd. reported revenue of Rs 35.47 crore and a profit of Rs 3.12 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Bafna Pharmaceuticals Q2 results preview.

Net profit in that base quarter was above the Rs 0.08 crore just reported for Q1 FY27, so the year-on-year comparison starts from a demanding level. Revenue of Rs 35.47 crore sits above the Rs 26.58 crore of the June 2026 quarter, which frames how much sequential movement the Bafna Pharmaceuticals Q2 results print needs to show growth.

Bafna Pharmaceuticals Quarterly Results Trend Over the Last Four Quarters

Quarter	Revenue (Rs Cr)	Net Profit (Rs Cr)
Q2 FY26 (Sep 2025)	35.47	3.12
Q3 FY26 (Dec 2025)	38.29	1.84
Q4 FY26 (Mar 2026)	42.24	2.75
Q1 FY27 (Jun 2026)	26.58	0.08

Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company's exchange filings, and they are the only basis this Bafna Pharmaceuticals Q2 results preview uses.

Revenue across those four quarters ranged from Rs 26.58 crore to Rs 42.24 crore, and net profit from Rs 0.08 crore to Rs 3.12 crore. That spread is the honest context for the Bafna Pharmaceuticals Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.

Key Factors That Could Shape Bafna Pharmaceuticals Q2 Results FY27

The Bafna Pharmaceuticals Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Bafna Pharmaceuticals has already reported.

Capacity Utilisation in Formulations

Oral solid dosage plants carry a largely fixed cost base, so how full the lines run decides margin more than product pricing does. A revenue fall of a third in one quarter compresses margin sharply.

Other Income Now Exceeds Operating Profit

Other income rose from Rs 0.60 crore to Rs 1.91 crore over the five quarters while operating profit fell from Rs 5.07 crore to Rs 0.89 crore. In Q1 FY27 it was more than double the operating result.

Stock Has Tripled Off a Low Base

The shares trade at Rs 301.60 against a 52-week low of Rs 94.77 with a 14-day RSI of 77.57, at a price-to-earnings ratio of 91.46 and 7.43 times a book value of Rs 40.60.

Bafna Pharmaceuticals Q2 Results FY27: Share Price and Valuation Going Into the Print

Bafna Pharmaceuticals share price today is Rs 301.60 on the NSE, down Rs 6.15 or 2.00% from the previous close of Rs 307.75 on 9 September 2026, ahead of the Bafna Pharmaceuticals Q2 results announcement.

Metric	Value (9 September 2026)
NSE Symbol	BAFNAPH
Current Market Price	Rs 301.60
52-Week High	Rs 318.50
52-Week Low	Rs 94.77
Market Capitalisation	Rs 712.52 crore
PE Ratio	91.46
PB Ratio	7.43
EPS (TTM)	Rs 3.30
Book Value per Share	Rs 40.60
Debt to Equity	0.39
Return on Equity	12.30%
50-Day Moving Average	Rs 255.17
200-Day Moving Average	Rs 166.25
RSI (14)	77.57

The stock trades above both its 50-day average of Rs 255.17 and its 200-day average of Rs 166.25, with a 14-day RSI of 77.57. None of this is a view on where the shares go once the Bafna Pharmaceuticals Q2 results are announced, and no price target is offered here.

Download the Univest iOS App or Univest Android App to track Bafna Pharmaceuticals Ltd. live price and quarterly earnings updates.

What Investors Should Watch When Bafna Pharmaceuticals Q2 Results Are Announced

Four lines carry most of the information in a company of this size, and reading them in order keeps the Bafna Pharmaceuticals Q2 results print in proportion.

1. Revenue against the Rs 35.47 crore reported in the September 2025 base quarter
2. Net profit against a profit of Rs 3.12 crore in that same quarter
3. Operating margin against 3.35% in Q1 FY27
4. Any exceptional item, provision or one-off gain disclosed alongside the numbers

A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Bafna Pharmaceuticals Q2 results announcement should be read together with the notes to the results rather than the headline alone.

Conclusion on Bafna Pharmaceuticals Q2 Results FY27

The Bafna Pharmaceuticals Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Bafna Pharmaceuticals Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.

On that basis the Bafna Pharmaceuticals Q2 results FY27 print faces a base of Rs 35.47 crore in revenue and a profit of Rs 3.12 crore, with the most recent quarter having delivered Rs 26.58 crore and a profit of Rs 0.08 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Bafna Pharmaceuticals, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.

FAQs on Bafna Pharmaceuticals Q2 Results FY27

What is the Bafna Pharmaceuticals Q2 results date for FY27?

Ans. The Bafna Pharmaceuticals Q2 results date for FY27 is not confirmed. Bafna Pharmaceuticals Ltd. had not filed a board meeting intimation with the NSE or BSE as of 9 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.

What quarter do the Bafna Pharmaceuticals Q2 results 2026 cover?

Ans. The Bafna Pharmaceuticals Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Bafna Pharmaceuticals Ltd. reports revenue, operating profit and net profit for that period, and the Bafna Pharmaceuticals Q2 results filing also carries the notes to the accounts.

What were the Bafna Pharmaceuticals Q1 FY27 results?

Ans. Bafna Pharmaceuticals Ltd. reported revenue of Rs 26.58 crore in Q1 FY27 and a profit of Rs 0.08 crore at the net level. Revenue was down 23.22% versus Q1 FY26 and net profit was down 97.64% from Rs 3.39 crore in Q1 FY26.

What were Bafna Pharmaceuticals Q2 FY26 results in the September 2025 quarter?

Ans. Bafna Pharmaceuticals Ltd. reported revenue of Rs 35.47 crore and a profit of Rs 3.12 crore in Q2 FY26. Operating margin was 12.07%. Those figures form the base for the Bafna Pharmaceuticals Q2 results FY27 comparison.

What are the main Bafna Pharmaceuticals Q2 results expectations this quarter?

Ans. No verified analyst estimate is publicly available. The Bafna Pharmaceuticals Q2 results expectations centre on revenue against the Rs 35.47 crore base, net profit against a profit of Rs 3.12 crore, operating margin against 3.35% in Q1 FY27, and any exceptional item disclosed with the numbers.

What is Bafna Pharmaceuticals share price today ahead of the Q2 earnings?

Ans. Bafna Pharmaceuticals share price is Rs 301.60 on the NSE as of 9 September 2026, down 2.00% from Rs 307.75. The stock is about 5.3% below its 52-week high of Rs 318.50 and 218.2% above its 52-week low of Rs 94.77, at a market capitalisation of Rs 712.52 crore.

Is Bafna Pharmaceuticals a good stock to buy before the Q2 results?

Ans. This article does not offer a buy, sell or hold recommendation on Bafna Pharmaceuticals Ltd.. The stock trades at a price-to-book ratio of 7.43 with a return on equity of 12.30%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.